Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model

Acta Neurochirurgica

Volumn 152, Issue 12, 2010, Pages 2161-2166

  Ulusal, Ismail ^a   Tari, Rabia ^a   Ozturk, Gulsah ^a   Aycicek, Ezgi ^a   Aktar, Fadime ^b   Kotil, Kadir ^c   Bilge, Turgay ^a   Kiris, Talat ^b  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Erythropoietin; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY WALL; ARTICLE; BRAIN VASOSPASM; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMORAL ARTERY; HISTOLOGY; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ERYTHROPOIETIN; FEMORAL ARTERY; INJECTIONS, INTRAPERITONEAL; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA; TUNICA MEDIA; VASOCONSTRICTION; VASOSPASM, INTRACRANIAL;

EID: 78651075524     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-010-0775-6     Document Type: Article

References (37)

1. Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N (2001) Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med Okayama 55:357-362
2. Ayer RE, Zhang JH (2008) Oxidative stress in subarachnoid haemorrhage: Significance in acute brain injury and vasospasm. Acta Neurochir Suppl 104:33-41
3. Banerjee D, Rodriguez M, Nag M, Adamson JW (2000) Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57:1895-1904
4. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073-2080
5. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643-651
6. Brines ML, Ghezzi P, Kenan S, Agnello D, de Laner Olle NC, Cerami C et al (2000) Erytropoetin crosses the blood brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(10):526-531
7. Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L (2009) Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci 21(10):7
8. Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L et al (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 103:5965-5970
9. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev Jul 18(3):CD000277. Review
10. d'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS (2007) Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 49:1142-1148
11. Grasso G, Buemi M, Corica F, Calapani G, Salpietro FM, Casuscelli T et al (2000) In vivo evidence that erythtropoetin has a neuro-protective effect during subarachnoid hemorrhage. Eur J Pharmacol 392:31-34
12. Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, Taki W (2008) Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: Evaluation using black blood magnetic resonance imaging. Neurobiol Dis 32:157-161
13. Kern M, Lam MM, Knuckey NW, Lind CR (2009) Statins may not protect against vasospasm in subarachnoid haemorrhage. J Clin Neurosci 16:527-530, Epub 2009
14. Kiris T, Karasu A, Yavuz C, Erdem T, Unal F, Hepgül K, Baloglu H (1999) Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. Acta Neurochir (Wien) 141:1323-1328, discussion 1328-1329
15. Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B (2009) Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 10:157-165
16. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2005) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242
17. Mayberg MR, Okada T, Bark DH (1990) Morphologic changes in cerebral arteries after subarachnoid hemorrhage. Neurosurg Clin N Am 1:417-432
18. Mayberg MR, Okada T, Bark DH (1990) The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg 72:626-633
19. Mori K, Miyazaki M, Hara Y, Aiko Y, Yamamoto T, Nakao Y (2009) Novel vasodilatory effect of intracisternal injection of magnesium sulfate solution on spastic cerebral arteries in the canine two-hemorrhage model of subarachnoid hemorrhage. J Neurosurg 110:73-78
20. Mori K, Miyazaki M, Iwata J, Yamamoto T, Nakao Y (2008) Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat. Neurosurg Rev 31:197-203, discussion 203
21. Murphy AM, Xenocostas A, Pakkiri P, Lee TY (2008) Hemodynamic effects of recombinanthuman erythropoietin on the central nervous system after subarachnoid hemorrhage: Reduction of microcirculatory impairment and functional deficits in a rabbit model. J Neurosurg 109:1155-1164
22. Okada T, Harada T, Bark DH, Mayberg MR (1990) A rat femoral artery model for vasospasm. Neurosurgery 27:349-356
23. Pluta RM (2008) Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Acta Neurochir Suppl 104:139-147, Review
24. Rinkel GJ, Feigin VL, Algra A, Vermeulen M, van Gijn J (2002) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 4:CD000277
25. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C et al (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97:609-613
26. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635-4640
27. Santhanam AV, Katusic ZS (2006) Erythropoietin and cerebral vascular protection:role of nitric oxide. Acta Pharmacol Sin 27:1389-1394, Review
28. Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS (2005) Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 36:2731-2737
29. Schubert GA, Schilling L, Thomè C (2008) Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: A laser Doppler flowmetry study in rats. J Neurosurg 109:1134-1140
30. Springborg JB, Møller C, Gideon P, Jørgensen OS, Juhler M, Olsen NV (2007) Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: A double blind randomised clinical trial. Acta Neurochir (Wien) 149:1089-1101, discussion 1101
31. Springborg JB, Sonne B, Frederiksen HJ, Foldager N, Poulsgaard L, Klausen T, Jorgensen OS, Olsen NV (2003) Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain. Brain Res 984:143-148
32. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP (1999) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 127:482-488
33. Sugawara T, Ayer R, Zhang JH (2008) Role of statins in cerebral vasospasm. Acta Neurochir Suppl 104:287-290
34. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K (2008) Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: Sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48:241-247, discussion 247-248
35. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: A Phase II randomized, double-blind, placebo-controlled trial. J Neurosurg 111:171-180
36. Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L (2007) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 27:552-563
37. Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5:71-78